Streptokinase and the Guillain-Barré Syndrome
Authors: JANET B. ARROWSMITH
Journal: Annals of Internal Medicine (1985)

Letters and Corrections1 August 1985Streptokinase and the Guillain-Barré SyndromeJANET B. ARROWSMITH, M.D., JULIE B. MILSTIEN, Ph.D., JOEL N. KURITSKY, M.D., GENESIO MURANO, Ph.D.JANET B. ARROWSMITH, M.D.Search for more papers by this author, JULIE B. MILSTIEN, Ph.D.Search for more papers by this author, JOEL N. KURITSKY, M.D.Search for more papers by this author, GENESIO MURANO, Ph.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-103-2-302_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Evaluation of the reported association between streptokinase therapy and the Guillain-Barré syndrome (1, 2) brings to light problems encountered by the Food and Drug Administration (FDA) in investigating serious, unexpected drug- or biologic-product-related events. Guillain-Barré syndrome has been reported to occur after viral and bacterial illnesses, immunization with swine influenza and other vaccines, surgical procedures, psychological disorders, and pregnancy (3). The syndrome is presumed to be the result of an abnormal immunologic process. Streptokinase, a bacterial protein, elicits a host immune response, and so, development of the syndrome after exposure to streptokinase may be biologically plausible.One...References1. LEAFMACDONALDKLIKSWILSONJONES DIBRS. Streptokinase and the Guillain-Barré syndrome [Letter]. Ann Intern Med. 1984;100:617. LinkGoogle Scholar2. EDEN K. Possible association of Guillain-Barré syndrome with thrombolytic therapy [Letter]. JAMA. 1983;249:2020-1. CrossrefMedlineGoogle Scholar3. SCHOENBERG B. Epidemiology of Guillian-Barré syndrome. Adv Neurol. 1978;19:249-60. MedlineGoogle Scholar4. SHARMACELLAPARISISASAHARA GGAA. Thrombolytic therapy. N Engl J Med. 1982;306:1268-76. CrossrefMedlineGoogle Scholar5. RUBIN R. Fibrinolysis and its current usage. Clin Ther. 1983;5:211-22. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: JANET B. ARROWSMITH, M.D.; JULIE B. MILSTIEN, Ph.D.; JOEL N. KURITSKY, M.D.; GENESIO MURANO, Ph.D.Affiliations: Center for Drugs and Biologics Food and Drug Administration Rockville, MD 20857*GRUBER HE. The origin of the origin of species. Review of Darwin and the Mysterious Mr. X. New Light on the Evolutionists. By: EISELEY L. The New York Times Book Review, 1979, July 22:16. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDrug-Induced Guillain-Barré SyndromeGuillain-Barre Syndrome after Streptokinase Therapy for Acute Myocardial InfarctionEncephalomyeloradiculoneuropathy following exposure to an industrial solventGuillain‐Barré syndrome complicating treatment with streptokinaseGuillain-Barr� syndrome during treatment with ofloxacinRhabdomyolysis due to combined treatment with lovastatin and cholestyramine.Nifedipine induced gingival abscesses.Guillain-Barre syndrome after treatment with streptokinase.EpidemiologyReferencesDrugs affecting blood coagulation and hemostasis 1 August 1985Volume 103, Issue 2Page: 302-302KeywordsBacterial diseasesDrug administrationDrug therapyFood and Drug AdministrationGuillain-Barre syndromeImmune responsePregnancyProteinsSwine influenzaVaccines ePublished: 1 December 2008 Issue Published: 1 August 1985 PDF downloadLoading ...